A fixed-dose topical combination of a potent synthetic corticosteroid (Fluocinolone acetonide) and a broad-spectrum imidazole antifungal agent (Miconazole). It is primarily indicated for the treatment of inflammatory dermatoses complicated by or at high risk of superficial fungal infections, particularly dermatophytoses and candidiasis. The corticosteroid component provides rapid anti-inflammatory, anti-pruritic, and vasoconstrictive effects, while the antifungal component treats the underlying or secondary infection. This combination is widely used in the Indian context for conditions like infected eczema, seborrheic dermatitis, and tinea corporis/cruris with significant inflammation.
Adult: Apply a thin film to the affected area twice daily, gently rubbing in. Treatment duration should be limited to 2-4 weeks. Re-evaluation by a physician is necessary if no improvement is seen within 1-2 weeks.
Note: Wash and dry the affected area thoroughly before application. Use fingertips to apply a thin layer and rub gently until absorbed. Wash hands after application unless hands are the treatment site. Do not bandage or wrap the area unless specifically instructed by a doctor (occlusion dramatically increases absorption and side effects). Avoid contact with eyes, nose, mouth, and other mucous membranes.
The combination exerts a dual mechanism: Fluocinolone acetonide binds to intracellular glucocorticoid receptors, modulating gene expression to inhibit phospholipase A2, thereby reducing the synthesis of pro-inflammatory mediators like prostaglandins and leukotrienes. It also inhibits the release of histamine and other cytokines, causing vasoconstriction. Miconazole inhibits the synthesis of ergosterol, a critical component of the fungal cell membrane, by blocking the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase. This leads to increased membrane permeability, leakage of cellular contents, and fungal cell death.
Pregnancy: Pregnancy Category C (US FDA). Topical corticosteroids, especially potent ones, should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Animal studies show teratogenicity with corticosteroids. Use the minimum effective amount for the shortest duration. Avoid large areas or prolonged use.
Driving: No effect on driving ability.
| Other Topical Corticosteroids | Additive risk of local and systemic corticosteroid side effects. | Major |
| Warfarin and other Coumarin Anticoagulants | Miconazole (if significantly absorbed) can inhibit CYP2C9/CYP3A4, potentially increasing anticoagulant effect and risk of bleeding. Monitor INR closely. | Major |
| Oral Hypoglycemic Agents (Sulfonylureas like Glimepiride, Glipizide) | Miconazole may potentiate their effect, increasing risk of hypoglycemia. | Moderate |
| Phenytoin, Carbamazepine | Miconazole may inhibit their metabolism, increasing risk of toxicity. | Moderate |
| Cyclosporine, Tacrolimus | Miconazole may increase their blood levels. Fluocinolone may alter immune response. | Moderate |
| Other CYP3A4 Substrates (e.g., Simvastatin, Lovastatin) | Potential for increased plasma levels if miconazole is absorbed systemically. | Moderate |
Same composition (Fluocinolone acetonide (0.01% w/w) + Miconazole (2% w/w)), different brands: